시장보고서

상품코드

1574933

세계의 포진성 피부염 시장 : 약물 유형별, 투여 경로별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 및 예측(2024-2032년)

Dermatitis Herpetiformis Market, By Drug Class, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 10월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 311 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

포진성 피부염 시장 규모는 2023년 3억103만 달러로 2024년부터 2032년까지 연평균 7.29%의 연평균 복합 성장률(CAGR)로 확대될 것으로 예상됩니다.

치료에는 일반적으로 엄격한 글루텐 제거 식단이 포함되어 증상을 완화하고 향후 발병을 예방하는 데 도움이 됩니다. 또한 가려움증과 염증을 완화하기 위해 약수처리도 시행됩니다. 환자의 삶의 질을 향상시키기 위해서는 조기 진단과 적절한 관리가 중요합니다.

포진성 피부염 시장 - 시장 역학

글루텐 과민증과 그 피부 증상에 대한 인식이 높아지면서 수요를 견인하고 있습니다.

글루텐 과민증과 포진성 피부염(DH)과 같은 피부 질환의 연관성에 대한 인식이 높아지면서 시장 성장의 주요 동인이 되고 있습니다. 점점 더 많은 사람들이 글루텐 불내성 증상을 인식하고 있으며, DH 검사 및 치료에 대한 수요가 증가하고 있습니다. 미국 국립보건원(NIH)에 따르면, 미국에서는 약 141명 중 1명이 DH와 밀접한 관련이 있는 체강 질병을 앓고 있다고 합니다. 이러한 인식 증가로 인해 의료진과 환자 모두 더 나은 검사 및 관리 옵션을 요구하고 있습니다. 이에 따라 제약회사와 의료기관은 이 질환을 치료할 수 있는 구체적인 치료법과 교육 자료를 개발하는 데 주력하고 있으며, 이는 시장 성장을 가속하고 있습니다.

포진성 피부염 시장 - 주요 인사이트

리서치 애널리스트의 분석에 따르면, 세계 시장은 예측 기간(2024-2032년) 동안 연평균 약 7.29%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

약물 유형별로는 Dapsone이 2023년 가장 큰 시장 점유율을 보일 것으로 예측됩니다.

투여 경로별로는 2023년 경구제가 주요 유형으로 부상했습니다.

최종 사용자별로는 2023년 병원이 주요 유형으로 부상했습니다.

지역별로는 북미가 2023년 매출 1위를 차지했습니다.

포진성 피부염 시장 - 세분화 분석 :

세계 포진성 피부염 시장은 약물 유형별, 투여 경로별, 최종 사용자별, 지역별로 세분화되어 있습니다.

약물 유형에 따라 뎁손, 국소 코르티코스테로이드, 항히스타민제 등 세 가지 범주로 나뉩니다. 가장 중요한 것은 Dapsone입니다. Dapsone은 항생제이며, 이 질환에 수반되는 가려움증과 염증을 억제하는 효과가 있습니다. 피부 병변이 사라지는 데 효과적이기 때문에 많은 의사들이 선호합니다. 즉각적인 효과와 증상 완화로 인해 치료 옵션 중 단연 돋보입니다. Dapsone의 효능은 광범위한 사용과 추천으로 이어져 대상포진 피부염 시장에서 Dapsone의 존재감을 높이고 있습니다.

시장은 투여 경로에 따라 경구제, 국소제, 주사제 등 두 가지 범주로 나뉩니다. 경구 투여 경로가 가장 중요하고 두드러집니다. Dapsone을 비롯한 경구용 치료제는 복용이 편리하고 증상을 효과적으로 완화시킬 수 있기 때문입니다. 경구 치료는 편리하고 비침습적이기 때문에 환자들은 경구 치료를 선호합니다. 주사제나 외용제를 선택할 수도 있지만, 불편함이나 잦은 도포 등의 이유로 선호도가 높지 않습니다. 전반적으로, 먹는 약은 포진성 피부염을 효과적으로 관리하는 데 중요한 역할을 합니다.

포진성 피부염 시장 - 지리적 통찰력

북미 대상포진 피부염 시장은 자가면역질환이 많고 피부질환에 대한 인식이 높기 때문에 중요한 시장입니다. 미국은 선진적인 의료 시스템과 강력한 연구 노력으로 이 시장을 선도하고 있습니다.

많은 임상시험과 승인으로 뒷받침되는 보다 혁신적인 치료법과 치료법이 점점 더 많이 출시되고 있습니다. 캐나다 역시 환자 교육 및 지원에 중점을 두면서 시장 성장의 한 축을 담당하고 있습니다. 이 지역에는 많은 대형 제약회사들이 진출해 있으며, 공동 연구와 기술 혁신이 활발하게 이루어지고 있습니다.

포진성 피부염 시장 - 경쟁상황:

포진성 피부염 시장은 경쟁이 치열하고 여러 주요 기업들이 진출해 있으며, GlaxoSmithKline, AbbVie, Novartis와 같은 주요 기업들이 자가면역성 피부질환 치료제를 개발하고 있습니다. 이들 기업은 기존 치료법을 개선하고 새로운 치료법을 개발하기 위해 연구에 투자하고 있으며, Pfizer와 Johnson & Johnson과 같은 기업들도 혁신적인 제품을 시장에 출시하고 있습니다.

또한, Aclaris Therapeutics와 같은 중소기업은 틈새 치료제를 전문적으로 개발하여 성장하고 있습니다. 전반적으로 포진성 피부염 관리를 강화하기 위한 공동 연구와 기술 혁신에 힘입어 상황은 역동적입니다.

서론
북미
- 개요
- 북미 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제11장 주요 벤더 분석 : 포진성 피부염 업계

경쟁 대시보드
기업 개요
- GlaxoSmithKline
- AbbVie
- Amgen
- Celgene(Bristol-Myers Squibb)
- Novartis
- Pfizer
- Johnson & Johnson
- Mylan
- Takeda Pharmaceuticals
- AstraZeneca
- Regeneron Pharmaceuticals
- Sanofi
- Eli Lilly and Company
- Dermira
- Aclaris Therapeutics
- Incyte Corporation
- Teva Pharmaceutical Industries

제12장 애널리스트의 전방위 전망

LSH 24.11.07

REPORT HIGHLIGHT

Dermatitis Herpetiformis Market size was valued at USD 301.03 Million in 2023, expanding at a CAGR of 7.29% from 2024 to 2032.

Dermatitis herpetiformis is a skin condition that causes itchy, blistering rashes. Dermatitis herpetiformis is linked to celiac disease, so it often occurs in people who cannot eat gluten, a protein found in wheat. When someone with celiac disease eats gluten, their body reacts by causing this skin rash. The rash usually appears on the elbows, knees, and buttocks but can show up anywhere on the body.

Treatment typically involves a strict gluten-free diet, which helps reduce symptoms and prevent future outbreaks. Medications can also be used to relieve itching and inflammation. Early diagnosis and proper management are important to improve the quality of life for those affected.

Dermatitis Herpetiformis Market- Market Dynamics

Growing awareness of gluten sensitivity and its skin manifestations drives demand.

The growing awareness of gluten sensitivity and its link to skin conditions like dermatitis herpetiformis (DH) is a key driver for the market. More people are recognizing the symptoms of gluten intolerance, which is increasing the demand for tests and treatments for DH. The National Institutes of Health (NIH) states that about 1 in 141 people in the U.S. has celiac disease, closely related to DH. This rising awareness encourages both healthcare providers and patients to seek better testing and management options. As a result, pharmaceutical companies and health organizations are focusing on developing specific treatments and educational materials to help address this condition, boosting market growth.

Dermatitis Herpetiformis Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.29% over the forecast period (2024-2032)

Based on Drug Class segmentation, Dapsone was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on End Users, Hospitals was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

Dermatitis Herpetiformis Market- Segmentation Analysis:

The Global Dermatitis Herpetiformis Market is segmented based on Drug Class, Route of Administration, End User, and Region.

The market is divided into three categories based on Drug Class: Dapsone, Topical corticosteroids, and Antihistamines. Dapsone is the most significant. Dapsone is an antibiotic that helps reduce itching and inflammation associated with the condition. It works effectively to clear up skin lesions, making it a preferred choice for many doctors. Its quick action and ability to provide relief from symptoms make it stand out in the treatment options. Dapsone's effectiveness leads to its wide use and recommendation, driving its prominence in the dermatitis herpetiformis market.

The market is divided into two categories based on the Route of Administration: Oral, Topical, and Injectable. The oral route of administration is the most significant and prominent. This is because oral medications, like dapsone and other treatments, are convenient to take and offer effective relief from symptoms. Patients prefer oral treatments since they are convenient and non-invasive, making it simpler to manage the condition over time. Injectable and topical options are available, but they are less favored due to factors like discomfort or the need for more frequent applications. Overall, oral medications play a key role in managing dermatitis herpetiformis effectively.

Dermatitis Herpetiformis Market- Geographical Insights

The North American Dermatitis Herpetiformis market is important because of the high number of autoimmune diseases and greater awareness of skin conditions. The United States leads this market, thanks to its advanced healthcare system and strong research efforts.

More innovative treatments and therapies are becoming available, backed by many clinical trials and approvals. Canada also plays a role in market growth by focusing on patient education and support. With many major pharmaceutical companies in the region, there's a lot of collaboration and innovation.

Dermatitis Herpetiformis Market- Competitive Landscape:

The Dermatitis Herpetiformis market is competitive, with several key players involved. Major companies like GlaxoSmithKline, AbbVie, and Novartis develop treatments for autoimmune skin diseases. They invest in research to improve existing therapies and create new ones. Firms like Pfizer and Johnson & Johnson also contribute innovative products to the market.

Furthermore, smaller companies like Aclaris Therapeutics are seeing growth by specializing in niche treatments. Overall, the landscape is dynamic, driven by collaboration and innovation to enhance the management of Dermatitis herpetiformis.

Recent Developments:

In May 2023, AbbVie's aesthetics division expanded its product lineup with a recent FDA approval for a new product called Skinvive. This approval, granted this week, added to Allergan's Juvederm dermal filler range.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DERMATITIS HERPETIFORMIS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GlaxoSmithKline
AbbVie
Amgen
Celgene (Bristol-Myers Squibb)
Novartis
Pfizer
Johnson & Johnson
Mylan
Takeda Pharmaceuticals
AstraZeneca
Regeneron Pharmaceuticals
Sanofi
Eli Lilly and Company
Dermira
Aclaris Therapeutics
Incyte Corporation
Teva Pharmaceutical Industries

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Dapsone
Topical corticosteroids
Antihistamines

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Topical
Injectable

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Dermatology Clinics
Homecare Settings
Others

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Dermatitis Herpetiformis Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Dermatitis Herpetiformis Market Snippet by Drugs Class
- 2.1.2. Dermatitis Herpetiformis Market Snippet by Route of Administration
- 2.1.3. Dermatitis Herpetiformis Market Snippet by End User
- 2.1.4. Dermatitis Herpetiformis Market Snippet by Country
- 2.1.5. Dermatitis Herpetiformis Market Snippet by Region
2.2. Competitive Insights

3. Dermatitis Herpetiformis Key Market Trends

3.1. Dermatitis Herpetiformis Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Dermatitis Herpetiformis Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Dermatitis Herpetiformis Market Opportunities
3.4. Dermatitis Herpetiformis Market Future Trends

4. Dermatitis Herpetiformis Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Dermatitis Herpetiformis Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Dermatitis Herpetiformis Market Landscape

6.1. Dermatitis Herpetiformis Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Dermatitis Herpetiformis Market - By Drugs Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drugs Class, 2023 & 2032 (%)
7.2. Dapsone
7.3. Topical corticosteroids
7.4. Antihistamines

8. Dermatitis Herpetiformis Market - By Route of Administration

8.1. Overview
- 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 8.1.2. Oral
- 8.1.3. Topical
- 8.1.4. Injectable

9. Dermatitis Herpetiformis Market - By End User

9.1. Overview
- 9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
- 9.1.2. Hospitals
- 9.1.3. Dermatology Clinics
- 9.1.4. Homecare Settings
- 9.1.5. Others

10. Dermatitis Herpetiformis Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Dermatitis Herpetiformis Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Dermatitis Herpetiformis Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.8. Italy
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. Italy Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.9. United Kingdom
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. United Kingdom Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.10. France
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. France Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.11. Russia
  - 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.2. Russia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.12. Netherlands
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Netherlands Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Sweden Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.14. Poland
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Poland Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.15. Rest of Europe
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Dermatitis Herpetiformis Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Dermatitis Herpetiformis Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Dermatitis Herpetiformis Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Dermatitis Herpetiformis Industry

11.1. Competitive Dashboard
11.2. Company Profiles
- 11.2.1. GlaxoSmithKline
- 11.2.2. AbbVie
- 11.2.3. Amgen
- 11.2.4. Celgene (Bristol-Myers Squibb)
- 11.2.5. Novartis
- 11.2.6. Pfizer
- 11.2.7. Johnson & Johnson
- 11.2.8. Mylan
- 11.2.9. Takeda Pharmaceuticals
- 11.2.10. AstraZeneca
- 11.2.11. Regeneron Pharmaceuticals
- 11.2.12. Sanofi
- 11.2.13. Eli Lilly and Company
- 11.2.14. Dermira
- 11.2.15. Aclaris Therapeutics
- 11.2.16. Incyte Corporation
- 11.2.17. Teva Pharmaceutical Industries

12. 360 Degree Analyst View

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us